XBiotech (XBIT) Cash & Equivalents (2014 - 2026)
XBiotech (XBIT) posted quarterly Cash & Equivalents of $125.6 million for Q4 2025, down 27.26% year-over-year from $172.7 million in Q4 2024, and down 14.77% quarter-over-quarter from $147.4 million in Q3 2025.
XBiotech (XBIT) Cash & Equivalents (2014 - 2026) Analysis & Trends
XBiotech's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $125.6 million for Q4 2025.
- In Q4 2025, Cash & Equivalents fell 27.26% year-over-year to $125.6 million; the TTM figure through Dec 2025 stood at $125.6 million (down 27.26% YoY), while the FY2025 annual figure was $125.6 million, down 27.26% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $125.6 million, down from $147.4 million in the prior quarter.
- The five-year high for Cash & Equivalents was $315.3 million in Q2 2021, with the low at $125.6 million in Q4 2025.
- The 5-year median for Cash & Equivalents is $185.8 million (2024), against an average of $191.6 million.
- The sharpest annual moves came in 2021 and 2023: Cash & Equivalents soared 37.26% in 2021, then plunged 36.49% in 2023.
- XBiotech's Cash & Equivalents stood at $237.0 million in 2021, then tumbled by 33.62% to $157.3 million in 2022, then increased by 27.16% to $200.0 million in 2023, then fell by 13.67% to $172.7 million in 2024, then fell by 27.26% to $125.6 million in 2025.
- Business Quant data shows XBIT's Cash & Equivalents at $125.6 million in Q4 2025, $147.4 million in Q3 2025, and $152.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | XBiotech | 69.51 Mn | 69.51 Mn | - | 109.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.53 Mn |
| Dec 31, 2025 | 125.60 Mn |
| Sep 30, 2025 | 147.37 Mn |
| Jun 30, 2025 | 152.94 Mn |
| Mar 31, 2025 | 155.90 Mn |
| Dec 31, 2024 | 172.68 Mn |
| Sep 30, 2024 | 183.12 Mn |
| Jun 30, 2024 | 188.50 Mn |
| Mar 31, 2024 | 201.00 Mn |
| Dec 31, 2023 | 200.02 Mn |
| Sep 30, 2023 | 202.19 Mn |
| Jun 30, 2023 | 143.40 Mn |
| Mar 31, 2023 | 152.48 Mn |
| Dec 31, 2022 | 157.31 Mn |
| Sep 30, 2022 | 160.57 Mn |
| Jun 30, 2022 | 225.79 Mn |
| Mar 31, 2022 | 231.82 Mn |
| Dec 31, 2021 | 236.98 Mn |
| Sep 30, 2021 | 238.90 Mn |
| Jun 30, 2021 | 315.30 Mn |